Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Advances in Protein Detection and Quantitation Methods

October 7, 2014 8:30 am | by Nuno Goncalves, Manager of Novel Biomolecular Detection, EMD Millipore | Articles | Comments

Protein detection and quantitation is required daily in thousands of laboratories worldwide for activities ranging from protein characterization to clinical diagnostic testing to drug dosing. Read more...                

TOPICS:

Icon Bioscience Reports Last Patient Out in Phase 3 Cataract Study

October 6, 2014 3:30 pm | News | Comments

Icon Bioscience Inc., a specialty biopharmaceutical company focused on utilizing its Verisome drug-delivery platform to develop unique intraocular eye-care therapeutics, announced that the last patient has completed treatment in its pivotal Phase 3 study of IBI-10090. Read more...

TOPICS:

Mylan Launches Generic HIV-1 Treatment

October 6, 2014 3:21 pm | News | Comments

Mylan Inc. announced the U.S. launch of its Lamivudine and Zidovudine Tablets USP, 150 mg/300 mg, which is the generic version of Viiv's Combivir. Read more...                                

TOPICS:
Advertisement

Sunesis Pharma Shares Sink

October 6, 2014 3:13 pm | News | Comments

Shares of Sunesis Pharmaceuticals tanked Monday, wiping out all their gains for 2014 and then some, after the drug developer said its treatment for an aggressive form of blood cancer missed its main goal in late-stage testing. Read more...       

TOPICS:

AbbVie's Humira Receives FDA Approval for JIA

October 6, 2014 3:04 pm | News | Comments

AbbVie announced that the FDA has approved the extension of the Humira indication for moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) to reducing signs and symptoms in patients ages 2 and older. Read more...

TOPICS:

Ariad and Bellicum Announce Revised License Agreement

October 6, 2014 2:52 pm | News | Comments

Ariad Pharmaceuticals Inc. and Bellicum Pharmaceuticals Inc. announced a restructuring of their license agreement for Ariad’s cell-signaling technology. Ariad will receive $50 million in exchange for a fully paid up license to this technology and return of its equity stake in closely held Bellicum. Read more... 

TOPICS:

BMS to Study Opdivo in Combination with Novartis' Lung Cancer Drugs

October 6, 2014 2:42 pm | News | Comments

 Bristol-Myers Squibb Company announced the establishment of a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of combining Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor Opdivo (nivolumab) with three molecularly targeted oncology therapies (Zykadia (ceritinib), INC280 and EGF816) from Novartis. Read more...

TOPICS:

Actavis Buying Durata Therapeutics for $616.4

October 6, 2014 10:39 am | News | Comments

Specialty pharmaceutical company Actavis is buying Durata Therapeutics Inc. for about $616.4 million to help bolster its infectious disease portfolio. Read more...                                    

TOPICS:
Advertisement

Teva Announces Results of Review of Core Specialty Therapeutic Areas

October 6, 2014 10:32 am | News | Comments

Teva Pharmaceutical announced results of its strategic review of core therapeutic areas for the company. The review included an extensive evaluation of Teva’s current and future capabilities to address unmet patient needs, the competitive landscape, barriers to entry and profitability with the purpose of creating a winning strategy to achieve global leadership in each of the company's core therapeutic areas. Read more...

TOPICS:

Alcobra Gets Positive Results for Adult ADHD Drug

October 6, 2014 10:22 am | News | Comments

Alcobra Ltd., an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, announced topline results from a Phase 3 study of Metadoxine Extended Release (MDX) in adults with ADHD. Read more...

TOPICS:

‘Programmable’ Antibiotic Harnesses Enzyme to Attack Drug-Resistant Microbes

October 6, 2014 10:12 am | News | Comments

The multitude of microbes scientists have found populating the human body have good, bad and mostly mysterious implications for our health. But when something goes wrong, we defend ourselves with the undiscriminating brute force of traditional antibiotics, which wipe out everything at once, regardless of the consequences. Read more...

TOPICS:

Journalist with Ebola Arrives at Nebraska Hospital

October 6, 2014 9:57 am | by Josh Funk | News | Comments

An American video journalist who contracted Ebola while working in Liberia has arrived at a Nebraska hospital, where he will be treated for the deadly disease. Ashoka Mukpo, 33, arrived by ambulance Monday at the Nebraska Medical Center, where he will be kept in a specialized biocontainment unit built specifically to handle this type of illness. Read more...

TOPICS:

Sanofi Signs 15-Year Supply Agreement for Wearable Injectors with Unilife

October 6, 2014 9:47 am | News | Comments

Unilife Corporation, a developer and supplier of injectable drug delivery systems, announced the signing of a worldwide Master Services and Commercial Supply Agreement with Sanofi to be the sole provider of cartridge based wearable injectors for all of Sanofi's applicable large dose volume drugs, excluding insulins, for a minimum 15 years. Read more...

TOPICS:

CEL-SCI Enrolls 16 New Patients in Phase 3 Cancer Trial

October 3, 2014 3:33 pm | News | Comments

CEL-SCI Corp. announced that during the month of September the company enrolled 16 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase 3 trial. Read more...             

TOPICS:

New Technology Isolates Tumor Cells from Blood to Optimize Cancer Therapy

October 3, 2014 3:29 pm | News | Comments

A team of bioengineers, molecular biologists, and clinicians used a novel rare cell-sorter to isolate breast cancer cells from the blood of patients, with the aim of identifying the most effective drugs to treat each individual tumor. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading